Biotech: Collaboration vs. Competition in Developing Affymax
Abstract/Contents
- Abstract
- Ringold talks about the decision to move away from being a technology based company at Affymax to applying the technology to pharma because of the relatively small life of a leading technology. Because of lack on internal infrastructure, they decided to sell the company and put it into the hands of a bigger company that had the infrastructure and expertise to use the technology. After a global search, Glaxo bought Affymax, he says.
Description
| Type of resource | moving image |
|---|---|
| Extent | 1 digital video file |
| Place | Stanford (Calif.) |
| Date created | February 26, 2003 |
| Language | English |
| Digital origin | born digital |
| Sound content | sound |
| Color content | color |
Creators/Contributors
| Speaker | Ringold, Gordon |
|---|
Subjects
| Subject | Entrepreneurship |
|---|---|
| Subject | Business |
| Genre | Filmed lectures |
Bibliographic information
| Location | https://purl.stanford.edu/yp448rb1043 |
|---|---|
| Location | SC1209 |
| Repository | Stanford University. Libraries. Department of Special Collections and University Archives |
Access conditions
- Use and reproduction
- The materials are open for research use and may be used freely for non-commercial purposes with an attribution. For commercial permission requests, please contact the Stanford University Archives (archivesref@stanford.edu).
- Copyright
- Copyright © 2003 The Board of Trustees of the Leland Stanford Junior University. All rights reserved.
Collection
Stanford Technology Ventures Program, Entrepreneurial Thought Leaders Seminar, videorecordings
View other items in this collection in SearchWorksAlso listed in
Loading usage metrics...